Optimapharm announces Sara Weytjens as Vice President, Regulatory and Site Activation
Optimapharm, a leading, mid-sized, full-service CRO across Europe and North America, is excited to announce the appointment of Sara Weytjens as Vice President, Regulatory and Site Activation, effective April 2023
“Throughout my career, I have been blessed with many opportunities on my path and to learn from stimulating & enlightening managers along that journey. I’m looking forward to the exciting challenge of evolving the Regulatory and Start-Up department at Optimapharm, supporting my team, our organization and serving our clients. To quote Robert Collier, “Success is the sum of small efforts, repeated day-in and day-out.”
Sara Weytjens, Vice President, Regulatory and Site Activation
We Deliver on Your Promises
Sara Weytjens has joined Optimapharm bringing extensive experience in clinical operations, regulatory affairs, and project management. Her professional career in clinical operations started in 1999 as CRA for both CRO and Pharma prior to joining Pharm-Olam CRO in 2004 to continue her professional development as Lead CRA, Project Manager, Clinical Operations Manager and Country Manager during several years. From 2016, Sara was leading Regulatory Affairs and developed significant expertise in transforming the Regulatory Affairs department into a Global Site Activation Unit covering regulatory, start-up management, site contract and budget, and green light package approval processes.
From January 2022, Sara worked to prepare her company for new CTR having experience getting approvals in CTIS.
Sara holds an MSc in Biochemistry from the University of Leuven, Belgium, and is a Board Member of BeCRO.
